The lognormal distribution as a fit to symptom durations in the range 0-2 years for 26,000 cancer patients. by Mould, R. F. et al.
Br. J. Cancer (1987), 56, 687-689 The Macmillan Press Ltd., 1987
SHORT COMMUNICATION
The lognormal distribution as a fit to symptom durations in the range
0-2 Years for 26,000 cancer patients
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Very little information on symptom durations of cancer
patients has been published in the literature and not even a
table of typical symptom duration ranges for different cancer
sites can be found. Nevertheless data on symptom duration
if available can provide useful information when studying
the natural history of the disease and when investigating
possible correlations between symptom duration and post-
treatment survival (Mould, 1985). However, when cancer
registries changed from manual to computer systems, many
which previously stored symptom durations discontinued this
practice. In addition, during system changeovers some
registries actually destroyed the relevant record cards from
the earlier registration years. These factors make it extremely
difficult in the United Kingdom to now obtain raw data on
symptom duration. Consequently we have been fortunate in
obtaining some 29,000 symptom durations for 26 different
cancer sites. In a few instances the numbers were sufficiently
large and the data sufficiently detailed for us to study site
subgroups. These few subgroups were:
By stage (1, 2, 3, 4) for breast and cervix;
By anatomical subsite (glottic, supraglottic, subglottic) for
larynx;
By treated or untreated group for rectum.
There were insufficient numbers of cases for time trends to
be studied. The records were obtained from eight cancer
registries in London, Birmingham, Bristol, Liverpool,
Manchester and Sutton (Table I).
One disadvantage of recorded symptom durations is that
patients often round their estimates to figures such as 3, 6,
12 or 24 months. However, when there was a relatively large
number in a particular site group we repeatedly grouped the
frequency data for model fitting using different symptom
duration intervals. It was found that this did not alter the
final outcome and therefore rounding errors do not
significantly bias our data. Using a chi-squared test, a
significance level of P>0.05 was chosen to accept the
hypothesis that the observed symptom durations in the range
0-2 years are a good fit to a lognormal model for 0-2 years.
It is emphasised that our technique was to estimate the
lognormal parameters by fitting the model to the data and
that the technique was not to fix a given pair of parameters
M and S and then in effect say 'Does this fit, P>0.05?'. It
should therefore be realised that it is not valid to use the
model to predict symptom duration patterns beyond 2 years.
Our decision to truncate the observed data at 2 years was
made to improve data validity, since we believe that any
patient estimation of symptom duration in excess of 2 years
could be prone to large errors. This view was supported
when asking colleagues to estimate time lapses from events
which occurred more than two years ago.
The lognormal distribution was chosen for study since it is
known to represent many positively skewed frequency
distributions in nature, such as infant mortality rates (Schrek
& Lipson, 1941), response times for different drugs (Gaddum,
1945; Lea, 1945) and the survival times of cancer patients
who die with their disease present (Boag, 1949), especially
those with cancers of the cervix (Mould & Boag, 1975) and
Table I Grouping by registry, site and treatment period
Number of cases
in group
Registry Treatment From 0-2 All
code period Site group years durations
WEST 1945-70 Bladder 421 477
BIRM 1970-76 Brain 1,594 1,735
MANC 1962-74 Breast, stage I 290 313
MANC 1962-74 Breast, stage II 202 213
MANC 1962-74 Breast, stage III 587 740
MANC 1962-74 Breast, stage IV 389 522
MANC 1947-61 Cervix, stage I 525 561
MANC 1947-51 Cervix, stage II 678 712
MANC 1947-51 Cervix, stage III 580 614
MANC 1947-61 Cervix, stage IV 478 520
GORD 1947-76 Colon 531 569
BIRM 1970-76 Hodgkin's disease 732 764
BIRM 1970-76 Kidney 869 905
LEDE 1933-73 Larynx, glottic 1,418 1,572
LEDE 1933-73 Larynx, subglottic 152 172
LEDE 1933-73 Larynx, supraglottic 441 479
LIVE 1970-79 Leukaemia 441 447
BRIS 1955-67 Lip 423 492
WEST 1960-70 Lung 554 563
BRIS 1955-67 Melanoma 314 428
LEDE 1933-73 Nasopharynx 529 552
BIRM 1970-76 Oesophagus 3,519 3,609
BRIS 1955-68 Oropharynx 104 104
THAM 1975-77 Ovary 1,687 1,704
THAM 1975-77 Pancreas 2,136 2,162
BRISa 1945-67 Penis 154 187
THAM 1975 Prostate 819 866
GORD 1947-76 Rectum, treated 864 921
GORD 1947-76 Rectum, untreated 99 109
BRIS 1955-60 Skin, basal cell 1,009 1,833
BRIS 1955-60 Skin, squamous cell 467 642
WEST 1945-70 Stomach 715 783
BIRM 1970-76 Testis 442 467
LIVE 1970-79 Thyroid 203 217
LEDE 1933-73 Tongue 516 548
LIVE 1970-79 Uterus 1,067 1,096
LIVE 1970-79 Vagina 70 71
Totals 26,019 28,669
(=91%) (= 100%)b
Registry codes: BIRM =Birmingham (West Midlands) Regional;
BRIS =South West (Bristol+Plymouth) Regional; BRISa =Plymouth
only; GORD =Gordon Hospital, London; LEDE =Personal registry
records of Dr M. Lederman, Royal Marsden Hospital, London;
LIVE =Mersey (Liverpool) Regional; MANC =Christie Hospital,
Manchester; THAM =Thames Region, Sutton; WEST =Westminster
Hospital.
Abbreviations: Squamous =Squamous cell carcinoma; Basal=
Basal cell carcinoma.
bNote: Only 9% of all recorded symptom durations were greater
than 2 years and therefore have not been used in this analysis.
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cancers of the head and neck (Mould et al., 1976). The
lognormal distribution is:
af(T)= 1 exp(- [loge(T/M)]2/2S2). TS,/2i7
Where T is the symptom time
Where M=exp(x) and is median of the lognormal dist
Where S is the standard deviation
I n
S2= E10 [lg(Xi_- ]2
n-li=
and
n
xZ=(1/n) ElogXi
i=l1
the xi are the individual symptom times.
Model fitting using chi-squared tests were accomplished
using software written for use with the Hewlett-Packard 86B
microprocessor based Westminster Hospital Cancer Registry
(Mould, 1982) and the results are shown in Table II for 37
data groups relating to 26 cancer sites. An alternative model
fitting computer program is published by McKintosh &
McKintosh (1980) in an appendix to their book on
modelling in endocrinology.
The two parameter lognormal model provided a good fit,
P>0.05, for all 37 data groups although the values of M and
S differed among the groups. Our estimates of the minimum
chi-squared parameters, termed M* and S*, are given in
Table II together with information on whether a fit to the
model was obtained with different values of S in the range
0.30 to 0.90, with discrete intervals of 0.05.
The minimum chi-squared estimate of the mean logtime,
M* in Table II, is in good agreement with the observed
median symptom duration, as would be expected. The range
of M* for 35 of the 37 site groups is 9 months, 1<M*< 10,
with only basal cell carcinoma of the skin and stage IV
breast cancer having larger values ofM*, respectively 18.8 and
12.5 months. Patients with late stage (III and IV) breast cancer
with M*=9.9 and 12.5 months in general delay longer before
diagnosis than late stage cervical cancer patients for whom
M*= 5.0 and 6.2 months. Although for early stage (I and II)
breast cancer M* = 1.3 and 1.4 months, which is less than the
Table II Results ofchi-squared goodness-of-fit lognormal model testing
M-valuesfor different values ofthe lognormal parameter Sfor which a goodfit was
Lognormal obtained, P>0.05. Ifa goodfit was not obtained no valuefor M has been included in the
minimum table
Median chi-squared
ofall parameters S=
durations
Site group (months) M* S* 0.30 0.35 0.40 0.45 0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90
Bladder 4.9 4.5 0.58 3.9 4.3 4.6 5.1 - -
Brain 2.0 1.9 0.70 1.9 1.9 1.9 1.9 -
Breast, stage I 1.7 1.3 0.77 1.3 1.3 1.3 1.3 1.3 1.3
Breast, stage II 1.7 1.4 0.69 1.5 1.4 1.4 1.4 1.4 1.4 1.4
Breast, stage III 8.1 9.9 0.79 8.0 8.8 10.1 11.1
Breast, stage IV 12.9 12.5 0.70 11.1 11.1 12.5 14.0 -
Cervix, stage I 4.5 4.0 0.50 3.8 4.0 4.3 - - - - - -
Cervix, stage II 3.8 4.0 0.52 3.9 4.2 4.5
Cervix, stage III 5.1 5.0 0.41 5.0 5.3 - - - -
Cervix, stage IV 5.8 6.2 0.48 5.9 6.3 6.9 - - - - - -
Colon 5.1 5.3 0.63 5.2 5.8 6.0 6.3
Hodgkin's disease 2.6 2.4 0.44 2.4
Kidney 1.9 1.7 0.62 1.7 1.7 1.7 1.7 - - -
Larynx, glottic 5.5 5.3 0.40 5.2
Larynx, subglottic 6.9 7.2 0.55 6.6 7.2 8.1 8.9
Larynx, supraglottic 5.0 5.1 0.53 4.8 5.0 5.4 5.8 6.2
Leukaemia 1.8 1.8 0.49 1.8 1.8 1.8
Lip 5.4 5.1 0.46 - 5.0 5.4
Lung 1.9 1.9 0.55 1.8 1.9 1.9 1.9 2.0
Melanoma 7.2 8.2 0.57 6.7 7.8 9.0 -
Nasopharynx 5.1 5.0 0.41 4.8 5.2 5.6
Oesophagus 2.4 2.4 0.38 2.5 2.8
Oropharynx 1.9 2.1 0.46 2.1 2.1 2.1 2.1 2.2 - -
Ovary 1.7 1.6 0.58 1.6 1.6 1.6 -
Pancreas 0.9 1.0 0.64 1.1 1.0 1.0 -
Penis 5.8 5.6 0.65 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.8 6.2
Prostate 2.6 2.5 0.67 2.4 2.4 2.5 2.5 2.6 2.7 2.8
Rectum, treated 5.4 5.7 0.52 5.6 6.1 - - - - - -
Rectum, untreated 6.6 7.2 0.56 6.7 6.8 6.8 7.5 7.9 8.1 8.3 - -
Skin, basal cell 21.8 18.8 0.62 10.6 17.6 21.1 - - - -
Skin, squamous cell 10.6 9.8 0.66 8.7 9.6 10.7 - -
Stomach 4.0 4.1 0.61 3.9 4.1 4.4 4.7 - - -
Testis 2.6 2.4 0.55 2.4 2.4 2.4 2.5 - -
Thyroid 3.8 3.9 0.47 3.9 4.0 4.1 - -
Tongue 3.6 3.5 0.46 3.5 3.5 3.5 -
Uterus 3.6 3.6 0.46 3.6 3.8 - - - -
Vagina 2.6 2.5 0.39 2.8 2.8 2.8 2.8 3.0 3.1 - - - - -
Total number of groups for which a good fit to
the data was obtained, P>0.05 1 1 7 16 20 22 22 19 13 9 5 5 1
Abbreviations:. Squamous =Squamous cell carcinoma; Basal =Basal cell carcinoma;
logtime given in months as distinct from a logarithm of months.
M*=Minimum chi-squared estimate of the S* meanLOGNORMAL DISTRIBUTION TO CANCER SYMPTOM DURATION 689
M* =4.0 months for cancer of the cervix. The data are
relevant particularly for those who are trying to achieve
earlier diagnosis of these two cancers.
The lognormal model for the prediction of long-term
survival rates using a value assumed for the parameter S in
the range S=0.35, to 0.40 has been shown to be satisfactory
for cancer of the cervix (Mould & Boag, 1975) although
values in the range S=0.45 to 0.50 are better for cancer of
the head and neck (Mould et al., 1976). These models refer to
cancer follow-up after treatment, whereas the data under
discussion in this paper relate to the time before treatment.
In this case (Table II), the optimum values of S are in the
range 0.50 to 0.65, which represents a different family of
lognormal curves than those describing survival after
treatment.
For 30 of the 37 site groups the lognormal was found to
be a good fit for a range of values of S differing by at least
0.10, and in nine of these 30 groups, differing by at least 0.20
(Table II). Over this range of values of S for a given site
group the chi-squared estimate of M usually remained
reasonably stable. It is therefore suggested that the
lognormal distribution can be used in practice to provide a
first estimate of the frequency distribution of cancer symptom
durations in the range 0-2 years, particularly since no
alternative method exists.
We are most grateful to the many people from the cancer registries
who facilitated our efforts to obtain raw data on symptom duration,
or who in some instances provided computer outputs for us with the
data grouped in monthly intervals. Without such help this study
would have been impossible. In particular we are indebted to Mrs
Joy Adams, Dr Val Blair, Mrs Sandra Gravestock, Mr A.R.D.
Kilburn, the late Dr M. Lederman, Miss Gwen Redmayne, Mr R.
Skeet, Dr J.A.H. Waterhouse and Mrs Pat Watts.
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